Journal article icon

Journal article

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.

Abstract:

Background

Patients with impaired glucose tolerance have an elevated risk of cardiovascular (CV) death; however, the causes and risk factors associated with non-CV deaths are poorly understood.

Methods

The NAVIGATOR trial enrolled 9,306 participants with impaired glucose tolerance and CV disease or at high CV risk, with a median follow-up of 6.4 years. Using this population, we identified (1) the proportion of deaths attributed to CV, non-CV, and unknown causes, a...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1016/j.ahj.2016.12.011

Authors


de Souza Brito, F More by this author
Haffner, S More by this author
Expand authors...
Novartis Pharmaceuticals More from this funder
Publisher:
Elsevier Publisher's website
Journal:
American Heart Journal Journal website
Volume:
186
Pages:
73-82
Publication date:
2016-12-05
Acceptance date:
2016-12-22
DOI:
EISSN:
1097-6744
ISSN:
0002-8703
Pubs id:
pubs:681348
URN:
uri:bcc74d22-925c-45f8-9cae-1deb67af7484
UUID:
uuid:bcc74d22-925c-45f8-9cae-1deb67af7484
Local pid:
pubs:681348

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP